{"pmid": "8980774", "sentences": {"sent_1": {"Section": "METHODS", "text": "Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection .", "entities": {"entity_1": {"text": "Single-dose pharmacokinetics", "class": "Outcome", "negation": 0, "UMLS": "", "start": 0}, "entity_2": {"text": "delavirdine mesylate", "class": "Intervention", "negation": 0, "UMLS": "", "start": 3}, "entity_3": {"text": "didanosine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 6}, "entity_4": {"text": "human immunodeficiency virus infection", "class": "Participant", "negation": 0, "UMLS": "", "start": 10}}, "relations": {}}, "sent_2": {"Section": "METHODS", "text": "Delavirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1 ( HIV-1 ) that is currently being evaluated in combination regimens with various", "entities": {}, "relations": {}}, "sent_3": {"Section": "METHODS", "text": "nucleoside analogs , including didanosine .", "entities": {}, "relations": {}}, "sent_4": {"Section": "METHODS", "text": "Due to the pH-dependent solubility of delavirdine , the buffering agents in didanosine formulations may reduce delavirdine absorption .", "entities": {}, "relations": {}}, "sent_5": {"Section": "METHODS", "text": "To evaluate the potential interaction between these agents , 12 HIV-infected patients ( mean [ +/- standard deviation ] CD4+ cell count , 304 +/- 213/mm3 ) were enrolled in", "entities": {"entity_5": {"text": "potential interaction", "class": "Outcome", "negation": 0, "UMLS": "", "start": 3}, "entity_6": {"text": "HIV-infected", "class": "Participant", "negation": 0, "UMLS": "", "start": 10}, "entity_7": {"text": "CD4+ cell count", "class": "Participant", "negation": 0, "UMLS": "", "start": 19}, "attribute_1": {"text": "304 +/- 213/mm3 ) were enrolled in", "class": "measure", "negation": 0, "UMLS": "", "start": 23}}, "relations": {}}, "sent_6": {"Section": "METHODS", "text": "a three-way crossover single-dose study .", "entities": {}, "relations": {}}, "sent_7": {"Section": "METHODS", "text": "Didanosine ( 125 to 200 mg given as buffered tablets ) and delavirdine mesylate ( 400 mg ) pharmacokinetics were evaluated when each drug was given alone ( treatments A", "entities": {"entity_8": {"text": "Didanosine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 0}, "attribute_2": {"text": "125 to 200 mg", "class": "measure", "negation": 0, "UMLS": "", "start": 2}, "entity_9": {"text": "delavirdine mesylate", "class": "Intervention", "negation": 0, "UMLS": "", "start": 12}, "attribute_3": {"text": "400 mg", "class": "measure", "negation": 0, "UMLS": "", "start": 15}, "entity_10": {"text": "pharmacokinetics", "class": "Outcome", "negation": 0, "UMLS": "", "start": 18}, "entity_11": {"text": "given alone", "class": "Intervention", "negation": 0, "UMLS": "", "start": 25}}, "relations": {}}, "sent_8": {"Section": "METHODS", "text": "and B , respectively ) , when the two drugs were given concurrently ( treatment C ) , and when didanosine was given 1 h after delavirdine ( treatment D", "entities": {"entity_12": {"text": "B", "class": "Intervention", "negation": 0, "UMLS": "", "start": 1}, "entity_13": {"text": "given concurrently", "class": "Intervention", "negation": 0, "UMLS": "", "start": 11}, "entity_14": {"text": "treatment C", "class": "Intervention", "negation": 0, "UMLS": "", "start": 14}, "entity_15": {"text": "didanosine was given 1 h after delavirdine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 20}}, "relations": {}}, "sent_9": {"Section": "METHODS", "text": ") .", "entities": {}, "relations": {}}, "sent_10": {"Section": "METHODS", "text": "Delavirdine exposure was reduced by concurrent administration of didanosine .", "entities": {"entity_16": {"text": "Delavirdine exposure", "class": "Outcome", "negation": 0, "UMLS": "", "start": 0}, "attribute_4": {"text": "reduced", "class": "modifier", "negation": 0, "UMLS": "", "start": 3}, "entity_17": {"text": "concurrent administration of didanosine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 5}}, "relations": {}}, "sent_11": {"Section": "METHODS", "text": "The maximum drug concentration in serum ( Cmax ) was reduced from 7.22 +/- 4.0 to 3.51 +/- 1.9 microM , and the area under the concentration-time curve from 0", "entities": {"entity_18": {"text": "maximum drug concentration in serum ( Cmax )", "class": "Outcome", "negation": 0, "UMLS": "", "start": 1}, "attribute_5": {"text": "reduced", "class": "modifier", "negation": 0, "UMLS": "", "start": 10}, "attribute_6": {"text": "7.22 +/- 4.0 to 3.51 +/- 1.9 microM", "class": "measure", "negation": 0, "UMLS": "", "start": 12}, "entity_19": {"text": "area under the concentration-time curve", "class": "Outcome", "negation": 0, "UMLS": "", "start": 23}}, "relations": {}}, "sent_12": {"Section": "METHODS", "text": "h to infinity ( AUC0 -- > infinity ) was reduced from 22.5 +/- 14 to 14 +/- 5.7 microM.h .", "entities": {"entity_20": {"text": "h to infinity ( AUC0 -- > infinity )", "class": "Outcome", "negation": 0, "UMLS": "", "start": 0}, "attribute_7": {"text": "reduced", "class": "modifier", "negation": 0, "UMLS": "", "start": 10}, "attribute_8": {"text": "22.5 +/- 14 to 14 +/- 5.7 microM.h", "class": "measure", "negation": 0, "UMLS": "", "start": 12}}, "relations": {}}, "sent_13": {"Section": "METHODS", "text": "The extent of N-dealkylation , as indicated by the ratio of the N-dealkylated delavirdine AUC0 -- > infinity to the delavirdine AUC0 -- > infinity , was unchanged across study", "entities": {"entity_21": {"text": "extent of N-dealkylation", "class": "Outcome", "negation": 0, "UMLS": "", "start": 1}, "entity_22": {"text": "ratio of the N-dealkylated delavirdine AUC0 -- > infinity to the delavirdine AUC0 -- > infinity", "class": "Outcome", "negation": 0, "UMLS": "", "start": 9}, "attribute_9": {"text": "unchanged", "class": "modifier", "negation": 0, "UMLS": "", "start": 27}}, "relations": {}}, "sent_14": {"Section": "METHODS", "text": "treatments ( P = 0.708 ) .", "entities": {"attribute_10": {"text": "P = 0.708", "class": "measure", "negation": 0, "UMLS": "", "start": 2}}, "relations": {}}, "sent_15": {"Section": "METHODS", "text": "Reductions in didanosine exposure were observed during concurrent administration with delavirdine with a Cmax reduction from 4.65 +/- 2.0 to 3.22 +/- 0.59 microM and an AUC0 -- > infinity", "entities": {"attribute_11": {"text": "Reductions", "class": "modifier", "negation": 0, "UMLS": "", "start": 0}, "entity_23": {"text": "didanosine exposure", "class": "Outcome", "negation": 0, "UMLS": "", "start": 2}, "entity_24": {"text": "concurrent administration with delavirdine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 7}, "entity_25": {"text": "Cmax", "class": "Outcome", "negation": 0, "UMLS": "", "start": 13}, "attribute_12": {"text": "reduction", "class": "modifier", "negation": 0, "UMLS": "", "start": 14}, "attribute_13": {"text": "4.65 +/- 2.0 to 3.22 +/- 0.59 microM", "class": "measure", "negation": 0, "UMLS": "", "start": 16}, "entity_26": {"text": "AUC0 --", "class": "Outcome", "negation": 0, "UMLS": "", "start": 26}}, "relations": {}}, "sent_16": {"Section": "METHODS", "text": "reduction from 7.93 +/- 3.9 to 6.54 +/- 2.3 microM.h .", "entities": {"attribute_14": {"text": "reduction", "class": "modifier", "negation": 0, "UMLS": "", "start": 0}, "attribute_15": {"text": "7.93 +/- 3.9 to 6.54 +/- 2.3 microM.h", "class": "measure", "negation": 0, "UMLS": "", "start": 2}}, "relations": {}}, "sent_17": {"Section": "METHODS", "text": "Thus , concurrent administration of delavirdine and didanosine may reduce the AUC0 -- > infinity of both drugs , although the clinical significance of this reduction is unknown .", "entities": {"entity_27": {"text": "concurrent administration of delavirdine and didanosine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 2}, "attribute_16": {"text": "reduce", "class": "modifier", "negation": 0, "UMLS": "", "start": 9}, "entity_28": {"text": "AUC0 -- > infinity", "class": "Outcome", "negation": 0, "UMLS": "", "start": 11}, "entity_29": {"text": "both drugs", "class": "Intervention", "negation": 0, "UMLS": "", "start": 16}}, "relations": {}}, "sent_18": {"Section": "METHODS", "text": "Administration of delavirdine 1 h before didanosine avoided the interaction .", "entities": {"entity_30": {"text": "delavirdine 1 h before didanosine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 2}, "attribute_17": {"text": "avoided", "class": "modifier", "negation": 0, "UMLS": "", "start": 7}, "entity_31": {"text": "interaction", "class": "Outcome", "negation": 0, "UMLS": "", "start": 9}}, "relations": {}}, "sent_19": {"Section": "METHODS", "text": "Due to the single-dose nature of this study , these findings require further evaluation at steady state .", "entities": {}, "relations": {}}}}